Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Third mRNA COVID-19 vaccine dose in kidney transplant recipients
2022-000319-30Phase 4Completed
- Sponsor
- Institute for Clinical and Experimental Medicine
- Start
- Jan 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, single-arm trial of mRNA COVID-19 vaccine in coronavirus disease 2019 (COVID-19), sponsored by Institute for Clinical and Experimental Medicine. Primary endpoint: SARS-CoV-2 PCR positivity after 3rd dose of SARS-CoV-2 mRNA vaccine. Started Jan 2022; status: completed.
02
Drugs
mRNA COVID-19 vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-000319-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000319-30.